AstraZeneca to invest over $1 billion in Massachusetts, boost workforce

Oct 5 (Reuters) - AstraZeneca ‌said on ​Monday ​it would spend more than $1 billion in Massachusetts as part of its broader $50 ‌billion US investment plan, a move expected ⁠to expand its workforce in the state by more than ‌50% in the coming ‌years.

The Anglo-Swedish drugmaker also opened a new research and development center in Cambridge, Massachusetts, as ​part of the investment.

Here are key details:

• Global drugmakers including Pfizer , Roche and Eli Lilly ⁠have been expanding their US footprint, pledging billions of dollars to ​boost manufacturing and research as they seek to strengthen supply chains and increase ​domestic capacity.

• The 570,000-square-foot, 18-story ‌facility in Kendall Square will focus on developing treatments for cancer, chronic and ⁠rare diseases, as well as cell therapies, the drugmaker said.

• Together with AstraZeneca's nearby genomic medicine site, ⁠the center will house nearly 2,000 researchers and scientists.

• The ​new facility includes 10 floors of laboratories equipped with robotics, automation and artificial intelligence, the company said.

• The ‌Cambridge site joins AstraZeneca's other major US research center in Gaithersburg, Maryland.

• AstraZeneca ‌has 24 research, manufacturing, commercial and corporate sites ⁠in the US ‌and employs more ​than 25,000 people in the country.

(Reporting by Siddhi Mahatole in Bengaluru; Editing by Maju ‌Samuel)

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Morning Bid: It takes two to make a ceasefire
• Factbox-The main parties vying to form New Zealand's next government
• Taiwan says it is closely monitoring series of Chinese live-fire drills